ZSET-845
目录号 : GC31261
ZSET-845是一种认知增强剂，可增强大鼠海马胆碱乙酰转移酶(cholineacetyltransferase)活性。
Cas No.:324077-62-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Animal experiment: | Rats: The passive avoidance apparatus consists of a small illuminated chamber and a larger dark chamber. The two chambers are separated by a guillotine door. On the first and second days of testing, each rat is placed in the apparatus and left for 3 min to habituate to the apparatus. On the third day, an acquisition trial is performed. Oral administration of ZSET-845 (0.001, 0.01, 0.1 or 1 mg/kg), donepezil or tacrine (0.01, 0.1, 1 or 10 mg/kg) is given 60 min before the acquisition trial. Scopolamine (2 mg/kg) is intraperitoneally (i.p.) injected 20 min before the acquisition trial. Matched control rats received vehicle only[1]. |
References: [1]. Yamaguchi Y, et al. Ameliorative effects of azaindolizinone derivative ZSET845 on scopolamine-induced deficits in passive avoidance and radial-arm maze learning in the rat. Jpn J Pharmacol. 2001 Nov;87(3):240-4. | |
ZSET-845 is a cognitive enhancer which enhances choline acetyltransferase activity in the hippocampus in the rat.
ZSET-845 has no inhibitory action on AChE activity and enhances choline acetyltransferase (ChAT) activity in NB-1 cells[1].
Treatment with ZSET-845 at the dose of 0.01, 0.1 and 1 mg/kg significantly ameliorates impaired performance caused by scopolamine. Oral administration of ZSET-845 causes an increase in ChAT activity in the hippocampus. In the hippocampus, ZSET-845 (0.01, 0.1 or 1 mg/kg) significantly increases ChAT activity (112%, 113.8% or 108.7%, respectively) compared with matched vehicle-injected control rats[1]. Oral administration of ZSET845 at a dose of 1 or 10 mg/kg ameliorates learning impairment in passive avoidance task and enhanced ChAT activity in the basal forebrain, medial septum and hippocampus, and increases in the number of ChAT-immunoreactive cells in the medial septum in Ab-treated rats to the levels of vehicle-injected control rats[2].
[1]. Yamaguchi Y, et al. Ameliorative effects of azaindolizinone derivative ZSET845 on scopolamine-induced deficits in passive avoidance and radial-arm maze learning in the rat. Jpn J Pharmacol. 2001 Nov;87(3):240-4. [2]. Yamaguchi Y, et al. Antiamnesic effects of azaindolizinone derivative ZSET845 on impaired learning and decreased ChAT activity induced by amyloid-beta 25-35 in the rat. Brain Res. 2002 Aug 2;945(2):259-65.
| Cas No. | 324077-62-5 | SDF | |
| Canonical SMILES | O=C1N=C2C=CC=CN2C1(CC3=CC=CC=C3)CC4=CC=CC=C4 | ||
| 分子式 | C21H18N2O | 分子量 | 314.38 |
| 溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.1809 mL | 15.9043 mL | 31.8086 mL |
| 5 mM | 0.6362 mL | 3.1809 mL | 6.3617 mL |
| 10 mM | 0.3181 mL | 1.5904 mL | 3.1809 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。